Latest filings (excl ownership)
6-K
Invitation to the Annual General Meeting 2024
8 Apr 24
6-K
Current report (foreign)
8 Apr 24
6-K
Current report (foreign)
22 Mar 24
20-F
2023 FY
Annual report (foreign)
20 Mar 24
6-K
BioNTech Announces Fourth Quarter and Full Year 2023
20 Mar 24
6-K
BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
20 Mar 24
6-K
BioNTech to Present Clinical Data Updates For Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024
11 Mar 24
6-K
BioNTech Announces Planned Retirement of Sean Marett
7 Mar 24
S-8
Registration of securities for employees
15 Feb 24
6-K
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
8 Feb 24
6-K
BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305
31 Jan 24
6-K
Current report (foreign)
22 Jan 24
6-K
BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference
9 Jan 24
6-K
BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer
21 Dec 23
6-K
BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda
18 Dec 23
6-K
BioNTech and Australia’s State of Victoria Sign Agreement on Strategic Partnership to Strengthen mRNA Ecosystem
7 Dec 23
6-K
1 Welcome & Introductory Remarks Ryan Richardson Chief Strategy Officer
7 Nov 23
6-K
Current report (foreign)
6 Nov 23
6-K
BioNTech Announces Third Quarter 2023 Financial Results
6 Nov 23
6-K
Pfizer and BioNTech Announce Positive Topline Data for Influenza and COVID-19
26 Oct 23
6-K
BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023
23 Oct 23
6-K
BioNTech to Present Multiple Program Updates Across Modalities at ESMO Congress 2023
16 Oct 23
6-K
Update Regarding Pfizer’s Statement on COMIRNATY-Related Write-Offs
16 Oct 23
6-K
Current report (foreign)
11 Sep 23
6-K
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union
30 Aug 23
6-K
BioNTech Expands Management Board by Appointing James Ryan as Chief Legal Officer
14 Aug 23
6-K
Current report (foreign)
7 Aug 23
6-K
BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update
7 Aug 23
6-K
BioNTech Completes Acquisition of InstaDeep
31 Jul 23
6-K
Current report (foreign)
29 Jun 23
6-K
Current report (foreign)
26 Jun 23
6-K
Current report (foreign)
23 Jun 23
6-K
BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO
2 Jun 23
6-K
Current report (foreign)
2 Jun 23
6-K
Pfizer and BioNTech Provide Update on COVID-19 Vaccine Supply Agreement with the European Commission
26 May 23
6-K
Changes in the Supervisory Board of BioNTech SE and Voting Results from the Annual General Meeting 2023
25 May 23
6-K
Current report (foreign)
8 May 23
6-K
Current report (foreign)
8 May 23
6-K
BioNTech Announces First Quarter 2023 Financial Results and Corporate Update
8 May 23
6-K
Invitation to the Annual General Meeting 2023
13 Apr 23
Latest ownership filings
144
Notice of proposed sale of securities
28 Feb 24
SC 13D
Autolus Therapeutics plc
21 Feb 24
SC 13G/A
Medine GmbH
14 Feb 24
SC 13G/A
ATHOS KG
7 Feb 24
144
Notice of proposed sale of securities
4 Jan 24
144/A
Notice of proposed sale of securities (amended)
10 Oct 23
144
Notice of proposed sale of securities
29 Sep 23
144
Notice of proposed sale of securities
29 Sep 23
144/A
Notice of proposed sale of securities (amended)
14 Aug 23
144
Notice of proposed sale of securities
29 Jun 23
144
Notice of proposed sale of securities
28 Jun 23
SC 13G/A
Medine GmbH
22 Feb 23
SC 13G/A
ATHOS KG
14 Feb 23
SC 13G/A
Medine GmbH
14 Feb 22
SC 13G/A
ATHOS KG
11 Feb 22
SC 13G/A
Medine GmbH
16 Feb 21
SC 13G/A
MIG Verwaltungs AG
16 Feb 21
SC 13G/A
ATHOS KG
16 Feb 21
SC 13G
BioNTech SE
14 Feb 20
SC 13G
BioNTech SE
13 Feb 20
SC 13G
Beneficial ownership report
12 Feb 20
SC 13D
Neon Therapeutics, Inc.
23 Jan 20